{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:55:05Z","timestamp":1768830905676,"version":"3.49.0"},"reference-count":34,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Pulmonary fibrosis (PF) is a chronic and progressive interstitial lung disease.\nThere is no effective treatment for PF. Hepatocyte growth factor (HGF) has anti-inflammatory and antifibrotic\neffects but has limited potential owing to its short half-life.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>To increase the transfection efficiency of pVAX-HGF, we prepared polyethyleneiminepolyethylene\nglycol: polyethyleneimine\/pVAX-HGF (PEG-PEI: PEI\/pVAX-HGF) nanocomposite\nloaded with a plasmid encoding the HGF gene. The PEG-PEI:PEI\/pVAX-HGF characteristics, including\nmorphology, particle size, zeta-potential, and DNA entrapment efficiency, were investigated. The\npVAX-HGF nanocomposites with low toxicity and high transfection efficiency were screened by cell\nviability assay and cell transfection. The antifibrotic effect of pVAX-HGF nanocomposite on PF rats\ninduced by bleomycin (BLM) was evaluated by pulmonary function measurement, pathological examination\nand collagen content assay.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Different nanocomposites were prepared to deliver pVAX-HGF, in which mix1 (PEGPEI:\nPEI\/pVAX-HGF) has lower potential and better entrapment ability. PEG-PEI:PEI\/pVAX-HGF\n(N\/P=25) nanocomposite with low toxicity and high transfection efficiency was administered to PF\nrats. After treatment with mix 1\/pVAX-HGF, the index of lung function(including EF50, MV, TV, PEF\nand PIF) in mix 1\/pVAX-HGF group was higher than that of the PF group. The number of cells in\nBALF of the mix 1\/pVAX-HGF group was significantly lower than that of the PF groups, and the content\nof hydroxyproline(HYP) and collagen Type I (Col-I) in the lung of the mix 1\/pVAX-HGF group\nwas much lower than that of the PF groups in the early stage. The result of pathological examination\nshowed that rats in the mix1\/pVAX-HGF group showed obviously reduced alveolar septal thickening,\nfewer infiltrated inflammatory cells and less collagen deposition.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The PEG-PEI:PEI\/pVAX-HGF nanocomposite can ameliorate PF induced by BLM. The\npVAX-HGF nanocomposite is a latent therapeutic strategy for PF.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201819666220613145417","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T06:22:35Z","timestamp":1655274155000},"page":"1368-1379","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatocyte Growth Factor Delivered by Nanocomposites for Gene Therapy\nof Bleomycin-Induced Pulmonary Fibrosis in Rats"],"prefix":"10.2174","volume":"20","author":[{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Lu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjun","family":"Xiao","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Gao","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of\nXuzhou Medical University, 32 Meijian Road, Xuzhou, Jiangsu, 221006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Du","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.rmed.2018.12.015","volume":"147","author":"Heukels P.","year":"2019","unstructured":"Heukels P.; Moor C.C.; von der Th&#xFC;sen J.H.; Wijsenbeek M.S.; Kool M.; Inflammation and immunity in IPF pathogenesis and treatment. Respir Med 2019,147,79-91","journal-title":"Respir Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"E201","DOI":"10.3390\/jcm7080201","volume":"7","author":"Barratt S.L.","year":"2018","unstructured":"Barratt S.L.; Creamer A.; Hayton C.; Chaudhuri N.; Idiopathic pulmonary fibrosis (IPF): An overview. J Clin Med 2018,7(8),E201","journal-title":"J Clin Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000495046","volume":"97","author":"Bendstrup E.","year":"2019","unstructured":"Bendstrup E.; Wuyts W.; Alfaro T.; Chaudhuri N.; Cornelissen R.; Kreuter M.; Melgaard Nielsen K.; M&#xFC;nster A.B.; Myll&#xE4;rniemi M.; Ravaglia C.; Vanuytsel T.; Wijsenbeek M.; Nintedanib in idiopathic pulmonary fibrosis: Practical management recommendations for potential adverse events. Respiration 2019,97(2),173-184","journal-title":"Respiration"},{"key":"ref=4","first-page":"6326","volume":"25","author":"Ntolios P.","year":"2021","unstructured":"Ntolios P.; Archontogeorgis K.; Anevlavis S.; Bonelis K.; Paxinou N.; Voulgaris A.; Froudarakis M.; Steiropoulos P.; Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: A real-world observational study. Eur Rev Med Pharmacol Sci 2021,25(20),6326-6332","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1359-6101(01)00029-6","volume":"13","author":"Maulik G.","year":"2002","unstructured":"Maulik G.; Shrikhande A.; Kijima T.; Ma P.C.; Morrison P.T.; Salgia R.; Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002,13(1),41-59","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1513\/pats.201202-018AW","volume":"9","author":"Crestani B.","year":"2012","unstructured":"Crestani B.; Marchand-Adam S.; Quesnel C.; Plantier L.; Borensztajn K.; Marchal J.; Mailleux A.; Soler P.; Dehoux M.; Hepatocyte growth factor and lung fibrosis. Proc Am Thorac Soc 2012,9(3),158-163","journal-title":"Proc Am Thorac Soc"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1517\/13543784.2013.778972","volume":"22","author":"Chakraborty S.","year":"2013","unstructured":"Chakraborty S.; Chopra P.; Hak A.; Dastidar S.G.; Ray A.; Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin Investig Drugs 2013,22(4),499-515","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1164\/ajrccm.162.6.9908097","volume":"162","author":"Dohi M.","year":"2000","unstructured":"Dohi M.; Hasegawa T.; Yamamoto K.; Marshall B.C.; Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000,162(6),2302-2307","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.hepres.2004.09.002","volume":"30","author":"Ido A.","year":"2004","unstructured":"Ido A.; Moriuchi A.; Kim I.; Numata M.; Nagata-Tsubouchi Y.; Hasuike S.; Uto H.; Tsubouchi H.; Pharmacokinetic study of recombinant human hepatocyte growth factor administered in a bolus intravenously or via portal vein. Hepatol Res 2004,30(3),175-181","journal-title":"Hepatol Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"GE01","DOI":"10.7860\/JCDR\/2015\/10443.5394","volume":"9","author":"Ramamoorth M.","year":"2015","unstructured":"Ramamoorth M.; Narvekar A.; Non viral vectors in gene therapy- an overview. J Clin Diagn Res 2015,9(1),GE01-GE06","journal-title":"J Clin Diagn Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.msec.2016.07.066","volume":"68","author":"Pandey A.P.","year":"2016","unstructured":"Pandey A.P.; Sawant K.K.; Polyethylenimine: A versatile, multifunctional non-viral vector for nucleic acid delivery. Mater Sci Eng C 2016,68,904-918","journal-title":"Mater Sci Eng C"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1016\/j.biomaterials.2008.04.036","volume":"29","author":"Morille M.","year":"2008","unstructured":"Morille M.; Passirani C.; Vonarbourg A.; Clavreul A.; Benoit J.P.; Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008,29(24-25),3477-3496","journal-title":"Biomaterials"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/10826068.2016.1141302","volume":"46","author":"Hu C.","year":"2016","unstructured":"Hu C.; Cheng X.; Lu Y.; Wu Z.; Zhang Q.; Gram-scale production of plasmid pUDK-HGF with current good manufacturing practices for gene therapy of critical limb ischemia. Prep Biochem Biotechnol 2016,46(8),844-849","journal-title":"Prep Biochem Biotechnol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1089\/hum.2017.217","volume":"29","author":"Wang L.S.","year":"2018","unstructured":"Wang L.S.; Wang H.; Zhang Q.L.; Yang Z.J.; Kong F.X.; Wu C.T.; Hepatocyte growth factor gene therapy for ischemic diseases. Hum Gene Ther 2018,29(4),413-423","journal-title":"Hum Gene Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/biomedicines2040301","volume":"2","author":"Mungunsukh O.","year":"2014","unstructured":"Mungunsukh O.; McCart E.A.; Day R.M.; Hepatocyte growth factor isoforms in tissue repair, cancer, and fibrotic remodeling. Biomedicines 2014,2(4),301-326","journal-title":"Biomedicines"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e13794","DOI":"10.14814\/phy2.13794","volume":"6","author":"Correll K.A.","year":"2018","unstructured":"Correll K.A.; Edeen K.E.; Redente E.F.; Zemans R.L.; Edelman B.L.; Danhorn T.; Curran-Everett D.; Mikels-Vigdal A.; Mason R.J.; TGF beta inhibits HGF, FGF7, and FGF10 expression in normal and IPF lung fibroblasts. Physiol Rep 2018,6(16),e13794","journal-title":"Physiol Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e0125797","DOI":"10.1371\/journal.pone.0125797","volume":"10","author":"Raymond W.W.","year":"2015","unstructured":"Raymond W.W.; Xu X.; Nimishakavi S.; Le C.; McDonald D.M.; Caughey G.H.; Regulation of hepatocyte growth factor in mice with pneumonia by peptidases and trans-alveolar flux. PLoS One 2015,10(5),e0125797","journal-title":"PLoS One"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.20452\/pamw.2784","volume":"125","author":"Przybylski G.","year":"2015","unstructured":"Przybylski G.; Chorostowska-Wynimko J.; Dyczek A.; W\u0119drowska E.; Jankowski M.; Szpechci\u0144ski A.; Gi&#x17C;ycka A.; Goli\u0144ska J.; Kopi\u0144ski P.; Studies of hepatocyte growth factor in bronchoalveolar lavage fluid in chronic interstitial lung diseases. Pol Arch Med Wewn 2015,125(4),260-271","journal-title":"Pol Arch Med Wewn"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1164\/rccm.200212-1514OC","volume":"168","author":"Marchand-Adam S.","year":"2003","unstructured":"Marchand-Adam S.; Marchal J.; Cohen M.; Soler P.; Gerard B.; Castier Y.; Les&#xE8;che G.; Valeyre D.; Mal H.; Aubier M.; Dehoux M.; Crestani B.; Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003,168(10),1156-1161","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1165\/rcmb.2008-0217OC","volume":"40","author":"Shukla M.N.","year":"2009","unstructured":"Shukla M.N.; Rose J.L.; Ray R.; Lathrop K.L.; Ray A.; Ray P.; Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7. Am J Respir Cell Mol Biol 2009,40(6),643-653","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/hum.2012.098","volume":"24","author":"Gazdhar A.","year":"2013","unstructured":"Gazdhar A.; Temuri A.; Knudsen L.; Gugger M.; Schmid R.A.; Ochs M.; Geiser T.; Targeted gene transfer of hepatocyte growth factor to alveolar type II epithelial cells reduces lung fibrosis in rats. Hum Gene Ther 2013,24(1),105-116","journal-title":"Hum Gene Ther"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1089\/hum.2012.177","volume":"24","author":"Wang H.","year":"2013","unstructured":"Wang H.; Yang Y.F.; Zhao L.; Xiao F.J.; Zhang Q.W.; Wen M.L.; Wu C.T.; Peng R.Y.; Wang L.S.; Hepatocyte growth factor gene-modified mesenchymal stem cells reduce radiation-induced lung injury. Hum Gene Ther 2013,24(3),343-353","journal-title":"Hum Gene Ther"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1164\/ajrccm.156.6.9611057","volume":"156","author":"Yaekashiwa M.","year":"1997","unstructured":"Yaekashiwa M.; Nakayama S.; Ohnuma K.; Sakai T.; Abe T.; Satoh K.; Matsumoto K.; Nakamura T.; Takahashi T.; Nukiwa T.; Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med 1997,156(6),1937-1944","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mam.2018.08.004","volume":"65","author":"Chanda D.","year":"2019","unstructured":"Chanda D.; Otoupalova E.; Smith S.R.; Volckaert T.; De Langhe S.P.; Thannickal V.J.; Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med 2019,65,56-69","journal-title":"Mol Aspects Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"L715","DOI":"10.1152\/ajplung.00361.2009","volume":"298","author":"Crosby L.M.","year":"2010","unstructured":"Crosby L.M.; Waters C.M.; Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 2010,298(6),L715-L731","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"Dunbar C.E.","year":"2018","unstructured":"Dunbar C.E.; High K.A.; Joung J.K.; Kohn D.B.; Ozawa K.; Sadelain M.; Gene therapy comes of age. Science 2018,359(6372),eaan4672","journal-title":"Science"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e98919","DOI":"10.1371\/journal.pone.0098919","volume":"9","author":"Zhao X.","year":"2014","unstructured":"Zhao X.; Cui H.; Chen W.; Wang Y.; Cui B.; Sun C.; Meng Z.; Liu G.; Morphology, structure and function characterization of PEI modified magnetic nanoparticles gene delivery system. PLoS One 2014,9(6),e98919","journal-title":"PLoS One"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nano.2019.04.004","volume":"19","author":"Ke X.","year":"2019","unstructured":"Ke X.; Wei Z.; Wang Y.; Shen S.; Ren Y.; Williford J.M.; Luijten E.; Mao H.Q.; Subtle changes in surface-tethered groups on PEGylated DNA nanoparticles significantly influence gene transfection and cellular uptake. Nanomedicine 2019,19,126-135","journal-title":"Nanomedicine"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/j.biomaterials.2012.12.038","volume":"34","author":"Liu C.","year":"2013","unstructured":"Liu C.; Liu F.; Feng L.; Li M.; Zhang J.; Zhang N.; The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials 2013,34(10),2547-2564","journal-title":"Biomaterials"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2018.07.001","volume":"285","author":"Osman G.","year":"2018","unstructured":"Osman G.; Rodriguez J.; Chan S.Y.; Chisholm J.; Duncan G.; Kim N.; Tatler A.L.; Shakesheff K.M.; Hanes J.; Suk J.S.; Dixon J.E.; PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J Control Release 2018,285,35-45","journal-title":"J Control Release"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4939-7113-8_2","volume":"1627","author":"Liu T.","year":"2017","unstructured":"Liu T.; De Los Santos F.G.; Phan S.H.; The bleomycin model of pulmonary fibrosis. Methods Mol Biol 2017,1627,27-42","journal-title":"Methods Mol Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/mt.2016.182","volume":"24","author":"Duncan G.A.","year":"2016","unstructured":"Duncan G.A.; Jung J.; Hanes J.; Suk J.S.; The mucus barrier to inhaled gene therapy. Mol Ther 2016,24(12),2043-2053","journal-title":"Mol Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/(SICI)1521-2254(199909\/10)1:5<331:AID-JGM60>3.0.CO;2-8","volume":"1","author":"Ernst N.","year":"1999","unstructured":"Ernst N.; Ulrichsk&#xF6;tter S.; Schmalix W.A.; R&#xE4;dler J.; Galneder R.; Mayer E.; Gersting S.; Plank C.; Reinhardt D.; Rosenecker J.; Interaction of liposomal and polycationic transfection complexes with pulmonary surfactant. J Gene Med 1999,1(5),331-340","journal-title":"J Gene Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/mt.2014.89","volume":"22","author":"Schuster B.S.","year":"2014","unstructured":"Schuster B.S.; Kim A.J.; Kays J.C.; Kanzawa M.M.; Guggino W.B.; Boyle M.P.; Rowe S.M.; Muzyczka N.; Suk J.S.; Hanes J.; Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Mol Ther 2014,22(8),1484-1493","journal-title":"Mol Ther"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220613145417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205905\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220613145417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T16:49:02Z","timestamp":1691426942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205905\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201819666220613145417","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}